Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
David Henry MD
David Henry MD Advisory Board
Eric Jonasch MD
Eric Jonasch MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · August 20, 2015

Nintedanib Plus mFOLFOX6 as First-Line Therapy for Metastatic Colorectal Cancer

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Annals of Oncology
A Phase I/II, Open-Label, Randomized Study of Nintedanib Plus mFOLFOX6 Versus Bevacizumab Plus mFOLFOX6 in First-Line Metastatic Colorectal Cancer Patients
Ann. Oncol 2015 Aug 12;[EPub Ahead of Print], E Van Cutsem, H Prenen, G D'Haens, J Bennouna, A Carrato, M Ducreux, O Bouché, A Sobrero, L Latini, H Staines, Z Oum'Hamed, H Dressler, M Studeny, J Capdevila

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated